Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Osteoprotegerin.

× No keyword cloud information.

42 in total

Review 1. CD28, CTLA-4 and their ligands: who does what and to whom?

Authors: D M Sansom
Journal: Immunology Date: 2000-10 Impact factor: 7.397

2. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Authors: D L Lacey; H L Tan; J Lu; S Kaufman; G Van; W Qiu; A Rattan; S Scully; F Fletcher; T Juan; M Kelley; T L Burgess; W J Boyle; A J Polverino
Journal: Am J Pathol Date: 2000-08 Impact factor: 4.307

3. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

Authors: C Capparelli; P J Kostenuik; S Morony; C Starnes; B Weimann; G Van; S Scully; M Qi; D L Lacey; C R Dunstan
Journal: Cancer Res Date: 2000-02-15 Impact factor: 12.701

4. Osteoprotegerin and osteoclast differentiation factor in tooth eruption.

Authors: G E Wise; S J Lumpkin; H Huang; Q Zhang
Journal: J Dent Res Date: 2000-12 Impact factor: 6.116

5. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.

Authors: J E Fata; Y Y Kong; J Li; T Sasaki; J Irie-Sasaki; R A Moorehead; R Elliott; S Scully; E B Voura; D L Lacey; W J Boyle; R Khokha; J M Penninger
Journal: Cell Date: 2000-09-29 Impact factor: 41.582

6. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice.

Authors: D R Clohisy; M L Ramnaraine; S Scully; M Qi; G Van; H L Tan; D L Lacey
Journal: J Orthop Res Date: 2000-11 Impact factor: 3.494

Review 7. Regulation of the differentiation and function of osteoclasts.

Authors: T J Chambers
Journal: J Pathol Date: 2000-09 Impact factor: 7.996

8. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

Authors: J Li; I Sarosi; X Q Yan; S Morony; C Capparelli; H L Tan; S McCabe; R Elliott; S Scully; G Van; S Kaufman; S C Juan; Y Sun; J Tarpley; L Martin; K Christensen; J McCabe; P Kostenuik; H Hsu; F Fletcher; C R Dunstan; D L Lacey; W J Boyle
Journal: Proc Natl Acad Sci U S A Date: 2000-02-15 Impact factor: 11.205

9. Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats.

Authors: U Feige; Y L Hu; J Gasser; G Campagnuolo; L Munyakazi; B Bolon
Journal: Cell Mol Life Sci Date: 2000-09 Impact factor: 9.261

10. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Authors: H Min; S Morony; I Sarosi; C R Dunstan; C Capparelli; S Scully; G Van; S Kaufman; P J Kostenuik; D L Lacey; W J Boyle; W S Simonet
Journal: J Exp Med Date: 2000-08-21 Impact factor: 14.307

8 in total

1. Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.

Authors: Jerome T Higgs; Joo Hyoung Lee; Hong Wang; Vishnu C Ramani; Diptiman Chanda; Cherlene Y Hardy; Ralph D Sanderson; Selvarangan Ponnazhagan
Journal: Blood Adv Date: 2017-11-21

2. Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications.

Authors: Sarvraj Singh Kohli; Virinder Singh Kohli
Journal: Indian J Endocrinol Metab Date: 2011-07

Review 3. Bone disease in multiple myeloma: pathophysiology and management.

Authors: Abdul Hameed; Jennifer J Brady; Paul Dowling; Martin Clynes; Peter O'Gorman
Journal: Cancer Growth Metastasis Date: 2014-08-10

Review 4. The deep-sea natural products, biogenic polyphosphate (Bio-PolyP) and biogenic silica (Bio-Silica), as biomimetic scaffolds for bone tissue engineering: fabrication of a morphogenetically-active polymer.

Authors: Xiaohong Wang; Heinz C Schröder; Qingling Feng; Florian Draenert; Werner E G Müller
Journal: Mar Drugs Date: 2013-03-08 Impact factor: 5.118

5. Effect of breastfeeding on serum osteoprotegerin and soluble receptor activator of nuclear factor-kappa B ligand in full term neonates.

Authors: Mandana Rafeey; Amir Ghorbanihaghjo; Fardad Masoumi; Samira Alizadeh; Sina Davari Farid
Journal: Iran Red Crescent Med J Date: 2013-10-05 Impact factor: 0.611

Review 6. Myeloma Bone Disease: A Comprehensive Review.

Authors: Shiva Kumar Reddy Mukkamalla; Dhatri Malipeddi
Journal: Int J Mol Sci Date: 2021-06-08 Impact factor: 5.923

7. Colorimetric and fluorescent TRAP assays for visualising and quantifying fish osteoclast activity.

Authors: Lalith Prabha Ethiraj; En Lei Samuel Fong; Ranran Liu; Madelynn Chan; Christoph Winkler; Tom James Carney
Journal: Eur J Histochem Date: 2022-03-24 Impact factor: 3.188

8. Serum osteoprotegerin level in hemodialysis patients using low-flux reused dialyzer in relation to atherosclerosis.

Authors: Tung Do Van; Tuan Nguyen Minh; Quyen Dao Bui Quy; Toan Pham Quoc; Toan Nguyen Duy; Kien Nguyen Trung; Hoang Nguyen Cong; Lan Le Thi Huong; Huong Bui Thi Thu; Tien Tran Viet; Quyet Do; Mao Can Van; Thang Le Viet
Journal: J Clin Lab Anal Date: 2021-06-26 Impact factor: 2.352

8 in total